Inclusion body myositis: from genetics to clinical trials

被引:11
|
作者
Nagy, Sara [1 ,2 ]
Khan, Alaa [1 ,3 ]
Machado, Pedro M. [2 ,4 ]
Houlden, Henry [1 ]
机构
[1] UCL, Dept Neuromuscular Dis, UCL Queen Sq Inst Neurol, London, England
[2] Univ Basel, Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[3] King Abdullah Med City Makkah, Mol Diagnost Unit, Clin Lab Dept, Mecca, Saudi Arabia
[4] UCL, Ctr Rheumatol, Div Med, London, England
关键词
Sporadic inclusion body myositis; Hereditary inclusion body myositis; Genetic susceptibility; Inflammation; Neurodegeneration; Clinical trials; Gene therapy; RIMMED VACUOLES; DOUBLE-BLIND; RISK LOCI; MYOPATHY; MITOCHONDRIAL; ASSOCIATION; BIMAGRUMAB; EFFICACY; REVEALS; SAFETY;
D O I
10.1007/s00415-022-11459-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies and is characterized by a slowly progressive disease course with asymmetric muscle weakness of predominantly the finger flexors and knee extensors. The disease leads to severe disability and most patients lose ambulation due to lack of curative or disease-modifying treatment options. Despite some genes reported to be associated with hereditary IBM (a distinct group of conditions), data on the genetic susceptibility of sporadic IBM are very limited. This review gives an overview of the disease and focuses on the current genetic knowledge and potential therapeutic implications.
引用
收藏
页码:1787 / 1797
页数:11
相关论文
共 50 条
  • [21] Inclusion body myositis:clinical and myopathological features
    解恒革
    王鲁宁
    沈定国
    中华内科杂志, 1998, (Z1)
  • [22] Inclusion body myositis: Clinical and pathological boundaries
    Amato, AA
    Gronseth, GS
    Jackson, CE
    Wolfe, GI
    Katz, JS
    Bryan, WW
    Barohn, RJ
    ANNALS OF NEUROLOGY, 1996, 40 (04) : 581 - 586
  • [23] Inclusion body myositis: clinical features and pathogenesis
    Steven A. Greenberg
    Nature Reviews Rheumatology, 2019, 15 : 257 - 272
  • [24] Clinical and imaging features of inclusion body myositis
    Hosaka, A.
    Ishii, A.
    Tomidokoro, Y.
    Tsuji, H.
    Oda, A.
    Takuma, H.
    Ishii, K.
    Tamaoka, A.
    NEUROMUSCULAR DISORDERS, 2010, 20 (9-10) : 631 - 631
  • [25] Clinical characteristics of dysphagic inclusion body myositis
    Taira, Kenichiro
    Mori-Yoshimura, Madoka
    Yamamoto, Toshiyuki
    Oya, Yasushi
    Nishino, Ichizo
    Takahashi, Yuji
    NEUROMUSCULAR DISORDERS, 2023, 33 (02) : 133 - 138
  • [26] Clinical and Diagnostic Variability of Inclusion Body Myositis
    Khan, Sara
    Zhou, Lan
    NEUROLOGY, 2012, 78
  • [27] Seropositive Inclusion Body Myositis: The Clinical Spectrum
    Pedouim, Farzin B.
    Enam, Sameen
    Goyal, Namita
    Mozaffar, Tahseen
    ANNALS OF NEUROLOGY, 2013, 74 : S104 - S105
  • [28] SPORADIC INCLUSION BODY MYOSITIS: A LONGITUDINAL OBSERVATIONAL STUDY INVESTIGATING OUTCOME MEASURES FOR CLINICAL TRIALS
    Sangha, Gina
    Skorupinska, Iwona
    Germain, L.
    Bellin, A.
    Parton, Matthew
    Hanna, Michael
    Miller, James
    Hilton-Jones, David
    Freebody, Jane
    Machado, Pedro
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12): : E65 - E66
  • [29] A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis
    Naddaf, Elie
    Skolka, Michael P.
    Prokop, Larry
    Dimachkie, Mazen M.
    Hogrel, Jean-Yves
    Benveniste, Olivier
    Wang, Zhen
    Mandrekar, Jay
    West, Colin P.
    Murad, M. Hassan
    RHEUMATOLOGY, 2025,
  • [30] Inclusion body myositis
    Warman-Chardon, Jodi
    Breiner, Ari
    Bourque, Pierre R.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (26) : E914 - E915